Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. / Poulsen, Troels Dirch; Andersen, Lars Willy; Steinbrüchel, Daniel; Gøtze, Jens Peter; Jørgensen, Ole Steen; Olsen, Niels Vidiendal.
I: Journal of Cardiothoracic and Vascular Anesthesia, Bind 23, Nr. 3, 2008, s. 316-323.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery
AU - Poulsen, Troels Dirch
AU - Andersen, Lars Willy
AU - Steinbrüchel, Daniel
AU - Gøtze, Jens Peter
AU - Jørgensen, Ole Steen
AU - Olsen, Niels Vidiendal
N1 - Keywords: Aged; Cardiac Surgical Procedures; Double-Blind Method; Erythropoietin, Recombinant; Female; Humans; Inflammation Mediators; Male; Middle Aged; Postoperative Complications; Preoperative Care; Prospective Studies; Time Factors
PY - 2008
Y1 - 2008
N2 - OBJECTIVES: Cardiac surgery and cardiopulmonary bypass (CPB) induce an inflammatory reaction that may lead to tissue injury. Experimental studies suggest that recombinant human erythropoietin (EPO) independent of its erythropoietic effect may be used clinically as an anti-inflammatory drug. This study tested the hypothesis that 2 large doses of EPO administered shortly before CPB ameliorate the systemic inflammatory response to CPB.DESIGN AND SETTING: A prospective, double-blind, placebo-controlled and randomized study at a single tertiary care hospital.PARTICIPANTS: Patients scheduled for coronary artery bypass graft surgery with CPB.INTERVENTIONS: EPO (epoetin alfa, 500 IU/kg intravenously, n = 22) or placebo (n = 21) was administered 12 to 18 hours preoperatively and again at the induction of anesthesia.MEASUREMENTS AND MAIN RESULTS: CPB in both groups greatly increased plasma concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1beta, IL-1beta receptor antagonist, IL-6, IL-10, and N-terminal probrain natriuretic peptide (NT-proBNP). Compared with placebo, EPO at day 3 after CPB augmented the TNF-alpha response (p < 0.05) and at 2 hours after CPB increased NT-proBNP (p < 0.05). Also, EPO tended to enhance the CPB-induced increase in IL-1beta receptor antagonist (p = 0.057). Otherwise, EPO had no effect on pro- and antiinflammatory mediators compared with placebo.CONCLUSIONS: Two large doses of EPO given shortly before CPB do not reduce perioperative release of inflammatory cytokines. In contrast, EPO may augment the TNF-alpha and NT-proBNP response. Although the long-term clinical impact remains unknown, the findings do not support use of EPO as an anti-inflammatory drug in patients undergoing cardiac surgery.
AB - OBJECTIVES: Cardiac surgery and cardiopulmonary bypass (CPB) induce an inflammatory reaction that may lead to tissue injury. Experimental studies suggest that recombinant human erythropoietin (EPO) independent of its erythropoietic effect may be used clinically as an anti-inflammatory drug. This study tested the hypothesis that 2 large doses of EPO administered shortly before CPB ameliorate the systemic inflammatory response to CPB.DESIGN AND SETTING: A prospective, double-blind, placebo-controlled and randomized study at a single tertiary care hospital.PARTICIPANTS: Patients scheduled for coronary artery bypass graft surgery with CPB.INTERVENTIONS: EPO (epoetin alfa, 500 IU/kg intravenously, n = 22) or placebo (n = 21) was administered 12 to 18 hours preoperatively and again at the induction of anesthesia.MEASUREMENTS AND MAIN RESULTS: CPB in both groups greatly increased plasma concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-1beta, IL-1beta receptor antagonist, IL-6, IL-10, and N-terminal probrain natriuretic peptide (NT-proBNP). Compared with placebo, EPO at day 3 after CPB augmented the TNF-alpha response (p < 0.05) and at 2 hours after CPB increased NT-proBNP (p < 0.05). Also, EPO tended to enhance the CPB-induced increase in IL-1beta receptor antagonist (p = 0.057). Otherwise, EPO had no effect on pro- and antiinflammatory mediators compared with placebo.CONCLUSIONS: Two large doses of EPO given shortly before CPB do not reduce perioperative release of inflammatory cytokines. In contrast, EPO may augment the TNF-alpha and NT-proBNP response. Although the long-term clinical impact remains unknown, the findings do not support use of EPO as an anti-inflammatory drug in patients undergoing cardiac surgery.
KW - Aged
KW - Cardiac Surgical Procedures
KW - Double-Blind Method
KW - Erythropoietin
KW - Female
KW - Humans
KW - Inflammation Mediators
KW - Male
KW - Middle Aged
KW - Postoperative Complications
KW - Preoperative Care
KW - Prospective Studies
KW - Recombinant Proteins
KW - Time Factors
U2 - 10.1053/j.jvca.2008.08.018
DO - 10.1053/j.jvca.2008.08.018
M3 - Journal article
C2 - 18948032
VL - 23
SP - 316
EP - 323
JO - Journal of Cardiothoracic and Vascular Anesthesia
JF - Journal of Cardiothoracic and Vascular Anesthesia
SN - 1053-0770
IS - 3
ER -
ID: 10486919